Subsequently, the PRESENT trial (ClinicalTrials.gov identifier: NCT01479244) recruited lymph node-positive, low-to-moderate HER2-expressing early BC women, who were randomly assigned to granulocyte–macrophage colony-stimulating factor (GM-CSF) or NP-S combined with GM-CSF groups [119]. This evidence concerns the gene ERBB2 and breast cancer.